Abstract：
:Multiple testing problems in regulatory applications are often more challenging than the problems of handling a set of mathematical symbols representing multiple null hypotheses under testing. In the union-intersection setting, it is important to define a family of null hypotheses relevant to the clinical questions at issue. The distinction between primary endpoint and secondary endpoint needs to be considered properly in different clinical applications. Without proper consideration, the widely used sequential gate keeping strategies often impose too many logical restrictions to make sense, particularly to deal with the problem of testing multiple doses and multiple endpoints, the problem of testing a composite endpoint and its component endpoints, and the problem of testing superiority and noninferiority in the presence of multiple endpoints. Partitioning the null hypotheses involved in closed testing into clinical relevant orderings or sets can be a viable alternative to resolving the illogical problems requiring more attention from clinical trialists in defining the clinical hypotheses or clinical question(s) at the design stage. In the intersection-union setting there is little room for alleviating the stringency of the requirement that each endpoint must meet the same intended alpha level, unless the parameter space under the null hypothesis can be substantially restricted. Such restriction often requires insurmountable justification and usually cannot be supported by the internal data. Thus, a possible remedial approach to alleviate the possible conservatism as a result of this requirement is a group-sequential design strategy that starts with a conservative sample size planning and then utilizes an alpha spending function to possibly reach the conclusion early.
journal_name
J Biopharm Statjournal_title
Journal of biopharmaceutical statisticsauthors
Hung HM,Wang SJdoi
10.1080/10543400802541693subject
Has Abstractpub_date
2009-01-01 00:00:00pages
1-11; discussion 12-41issue
1eissn
1054-3406issn
1520-5711pii
907426452journal_volume
19pub_type
杂志文章abstract：:We would like to estimate the parameters of a dose-response function with the greatest precision as possible. For a two-parameter model, this is equivalent to minimizing the area of the confidence ellipsoid, i.e., a D-optimal design. Previous work on this particular model has included minimal designs. These designs ar...
journal_title：Journal of biopharmaceutical statistics
pub_type： 杂志文章
doi：10.1081/BIP-100101012
更新日期：2000-02-01 00:00:00
abstract：:During preclinical drug development, the immune system is specifically evaluated after prolonged treatment with drug candidates, because the immune system may be an important target system. The response of antibodies against a T-cell-dependent antigen is recommenced by the FDA and EMEA for the evaluation of immunosupp...
journal_title：Journal of biopharmaceutical statistics
pub_type： 杂志文章
doi：
更新日期：2005-01-01 00:00:00
abstract：:This paper addresses the problem of analyzing multivariate response with the variates having different distributions. We use the generalized estimating equations proposed by Prentice and Zhao (1) to estimate mean and covariance parameters. Wald statistics are used to test hypotheses about the parameters. Data from a t...
journal_title：Journal of biopharmaceutical statistics
pub_type： 杂志文章
doi：10.1080/10543409608835129
更新日期：1996-05-01 00:00:00
abstract：:The van Elteren test, as a type of stratified Wilcoxon-Mann-Whitney test for comparing two treatments accounting for stratum effects, has been used to replace the analysis of variance when the normality assumption was seriously violated. The sample size estimation methods for the van Elteren test have been proposed an...
journal_title：Journal of biopharmaceutical statistics
pub_type： 杂志文章
doi：10.1080/10543400600762939
更新日期：2006-01-01 00:00:00
abstract：:In the era of precision medicine, drugs are increasingly developed to target subgroups of patients with certain biomarkers. In large all-comer trials using a biomarker stratified design, the cost of treating and following patients for clinical outcomes may be prohibitive. With a fixed number of randomized patients, th...
journal_title：Journal of biopharmaceutical statistics
pub_type： 杂志文章
doi：10.1080/10543406.2017.1379532
更新日期：2018-01-01 00:00:00
abstract：:As more biologic products are going off patent protection, the development of follow-on biologic products (also known as biosimilars) has gained much attention from both the biotechnology industry and regulatory agencies. Unlike small molecules, the development of biologic products is not only more complicated but als...
journal_title：Journal of biopharmaceutical statistics
pub_type： 杂志文章
doi：10.1080/10543406.2014.941991
更新日期：2014-01-01 00:00:00
abstract：:Parameter estimation following an adaptive design or group sequential design has been extremely challenging due to potential random high from its face value estimate. In this paper, we introduce a new framework to model clinical trial data flow based on a marked point process (MPP). The MPP model allows us to use meth...
journal_title：Journal of biopharmaceutical statistics
pub_type： 杂志文章
doi：10.1080/10543406.2012.676534
更新日期：2012-01-01 00:00:00
abstract：:Failure to recognize the serious implications of heterogeneous correlations and disregard of the multiple test problem in interpreting the results from repeated measurements ANOVA of any single primary outcome measure can produce false-positive error rates that are more than five times the alpha level that is reported...
journal_title：Journal of biopharmaceutical statistics
pub_type： 杂志文章
doi：10.1080/10543409608835123
更新日期：1996-03-01 00:00:00
abstract：:The world of medical devices while highly diverse is extremely innovative, and this facilitates the adoption of innovative statistical techniques. Statisticians in the Center for Devices and Radiological Health (CDRH) at the Food and Drug Administration (FDA) have provided leadership in implementing statistical innova...
journal_title：Journal of biopharmaceutical statistics
pub_type： 杂志文章,评审
doi：10.1080/10543406.2015.1092037
更新日期：2016-01-01 00:00:00
abstract：:In 1968 the Food and Drug Administration (FDA) established the Adverse Event Reporting System (AERS) database containing data on adverse events (AEs) reported by patients, health care providers, and other sources through a spontaneous reporting system. FDA uses AERS for monitoring the safety of the drugs on the market...
journal_title：Journal of biopharmaceutical statistics
pub_type： 杂志文章
doi：10.1080/10543406.2013.736810
更新日期：2013-01-01 00:00:00
abstract：:Statistical methodologies for human abuse potential studies are rarely evaluated. Human abuse potential studies assess whether test drugs produce positive and negative subjective responses on abuse-related measures using volunteers with histories of recreational drug use. These studies typically have a randomized, dou...
journal_title：Journal of biopharmaceutical statistics
pub_type： 杂志文章
doi：10.1080/10543406.2011.616972
更新日期：2013-03-11 00:00:00
abstract：:How long a dementia patient is cared for in the home before admission to a nursing home depends on the state of the patient and the state of the caregiver. Using 5-year follow-up data, the times until entry to nursing home and until death are modeled using a Cox survival model in which patient and caregiver variables ...
journal_title：Journal of biopharmaceutical statistics
pub_type： 杂志文章
doi：10.1080/10543409408835076
更新日期：1994-03-01 00:00:00
abstract：:In this article, a parametric sequential test is proposed under the Weibull model. The proposed test is asymptotically normal with an independent increment structure. The sample size for a fixed sample test is derived for the purpose of group sequential trial design. In addition, a multi-stage group sequential procedu...
journal_title：Journal of biopharmaceutical statistics
pub_type： 杂志文章
doi：10.1080/10543406.2014.971165
更新日期：2015-01-01 00:00:00
abstract：:In recent years, development of biosimilar products has attracted considerable attention. Because of the structural complexity of biologics, it is difficult to demonstrate that a biosimilar product is identical to the reference product. Therefore, for the development of biosimilar products, we need to adopt an approac...
journal_title：Journal of biopharmaceutical statistics
pub_type： 杂志文章
doi：10.1080/10543406.2014.941983
更新日期：2014-01-01 00:00:00
abstract：:The issue of consistency and reliability arises frequently in applied clinical trials, and there is a considerable amount of literature on this topic. For a continuous random variable, we describe a process to assess whether the mean and variance are the same from one evaluation to the other and we derive the intracla...
journal_title：Journal of biopharmaceutical statistics
pub_type： 杂志文章
doi：10.1081/BIP-120022773
更新日期：2003-08-01 00:00:00
abstract：:In clinical trials of drug development, patients are often followed for a certain period of time, and the outcome variables are measured at scheduled time intervals. The main interest of the trial is the treatment efficacy at a prespecified time point, which is often the last visit. In such trials, patient dropout is ...
journal_title：Journal of biopharmaceutical statistics
pub_type： 杂志文章
doi：10.1080/10543400903242753
更新日期：2009-11-01 00:00:00
abstract：:One of the most critical decision points in clinical development is Go/No-Go decision-making after a proof-of-concept study. Traditional decision-making relies on a formal hypothesis testing with control of type I and type II error rates, which is limited by assessing the strength of efficacy evidence in a small isola...
journal_title：Journal of biopharmaceutical statistics
pub_type： 杂志文章
doi：10.1080/10543406.2018.1489400
更新日期：2019-01-01 00:00:00
abstract：:The problem of testing treatment difference in the occurrence of a study endpoint in a randomized parallel-group comparative clinical trial with repeated responses under the assumption that the responses follow a bivariate zero-inflated Poisson (ZIP) distribution is considered. Likelihood ratio test for homogeneity of...
journal_title：Journal of biopharmaceutical statistics
pub_type： 杂志文章
doi：10.1080/10543406.2014.919934
更新日期：2015-01-01 00:00:00
abstract：:An attractive application of expression technologies is to predict drug efficacy or safety using expression data of biomarkers. To evaluate the performance of various classification methods for building predictive models, we applied these methods on six expression datasets. These datasets were from studies using micro...
journal_title：Journal of biopharmaceutical statistics
pub_type： 杂志文章
doi：10.1081/BIP-200035491
更新日期：2004-11-01 00:00:00
abstract：:The study of drug combinations has become important in drug development due to its potential for efficacy at lower, less toxic doses and the need to move new therapies rapidly into clinical trials. The goal is to identify which combinations are additive, synergistic, or antagonistic. Although there exists statistical ...
journal_title：Journal of biopharmaceutical statistics
pub_type： 杂志文章
doi：10.1080/10543400902964019
更新日期：2009-07-01 00:00:00
abstract：:Multipopulation tailoring trials provide a trial design option that supports the realization of tailored therapeutics or personalized medicine. Several recent publications have focused on statistical and clinical considerations that arise in these trials that are designed to study the overall treatment effect in a pop...
journal_title：Journal of biopharmaceutical statistics
pub_type： 杂志文章,评审
doi：10.1080/10543406.2013.856025
更新日期：2014-01-01 00:00:00
abstract：:A main challenge in molecular diagnostic research is to accurately evaluate the performance of a new nucleic acid amplification test when the reference standard is imperfect. Several approaches, such as discrepant analysis, composite reference standard (CRS) method, or latent class analysis (LCA), are commonly applied...
journal_title：Journal of biopharmaceutical statistics
pub_type： 杂志文章
doi：10.1080/10543406.2018.1428613
更新日期：2018-01-01 00:00:00
abstract：:In clinical trials, it is important to set up a design to reach a decision on effectiveness of a drug in treating a disease with the loss of the minimum number of patients. Group sequential designs are very beneficial on this point. However, the proportional hazards assumption must hold to work under a group sequentia...
journal_title：Journal of biopharmaceutical statistics
pub_type： 杂志文章
doi：10.1080/10543406.2011.616975
更新日期：2013-03-11 00:00:00
abstract：:Recently, two CPMP Points to Consider, one on adjustment for baseline covariates and the other on multiplicity issues in clinical trials, have included recommendations on the use of subgroup analysis for regulatory purposes. However, despite their regular use and regulatory attention, the validity and nature of subgro...
journal_title：Journal of biopharmaceutical statistics
pub_type： 杂志文章
doi：10.1081/BIP-200067988
更新日期：2005-01-01 00:00:00
abstract：:This article discusses the design of a clinical trial where a new treatment will be compared to a control. For a specific type of endpoint, there are a wide variety of test statistics that can be used. Also, the investigator must decide how many patients to accrue in each arm as well as the duration of the study. Afte...
journal_title：Journal of biopharmaceutical statistics
pub_type： 杂志文章
doi：10.1081/bip-120015743
更新日期：2002-05-01 00:00:00
abstract：:When performing a pivotal clinical trial, it may be of interest to assess the probability of success (PoS) of that trial. Initially evaluated when the trial is designed, PoS can be updated as the trial progresses and new information about the drug effect becomes available. Such information can be external to the trial...
journal_title：Journal of biopharmaceutical statistics
pub_type： 杂志文章
doi：10.1080/10543406.2014.972508
更新日期：2016-01-01 00:00:00
abstract：:Nonparametric versions of normal theory step-down multiple-test procedures for inferring minimum effective dose (see Tamhane et al. (1)) were developed and studied by Monte Carlo simulation. Two types of step-down testing procedures were examined. For both procedures, pairwise, linear, or Helmert contrasts of mean ran...
journal_title：Journal of biopharmaceutical statistics
pub_type： 杂志文章
doi：10.1081/BIP-100101173
更新日期：1999-05-01 00:00:00
abstract：:It has been widely recognized that interim analyses of accumulating data in a clinical trial can inflate type I error. Different methods, from group sequential boundaries to flexible alpha spending functions, have been developed to control the overall type I error at prespecified level. These methods mainly apply to t...
journal_title：Journal of biopharmaceutical statistics
pub_type： 杂志文章
doi：10.1080/10543406.2014.901341
更新日期：2014-01-01 00:00:00
abstract：:Stability testing is a procedure frequently used in the pharmaceutical industry to estimate the shelf life of a drug. Hereby, a standard problem of interest is whether or not to pool a given number of batches to assign a single shelf life for the combined batches. In this paper, we propose two modified methods for the...
journal_title：Journal of biopharmaceutical statistics
pub_type： 杂志文章
doi：10.1080/10543400802287230
更新日期：2008-01-01 00:00:00
abstract：:Ratio of means (ROM) and difference of means (DOM) are often used in a superiority, noninferiority (NI), or average bioequivalence (ABE) test to evaluate whether the test mean is superior, NI, or equivalent to the reference (placebo or active control) mean. The literature provides recommendations regarding how to choo...
journal_title：Journal of biopharmaceutical statistics
pub_type： 杂志文章
doi：10.1080/10543406.2016.1265536
更新日期：2017-01-01 00:00:00
